关系血管扩张药品市场，监管禁止武汉用通收购山东华泰制药案

Core Viewpoint - The State Administration for Market Regulation (SAMR) has prohibited the acquisition of Shandong Huatai Pharmaceutical Co., Ltd. by Wuhan Yuntong Pharmaceutical Co., Ltd., marking a significant regulatory action under China's Anti-Monopoly Law [1][2]. Group 1: Regulatory Action - This case is the fourth prohibition of a business concentration since the implementation of the Anti-Monopoly Law in 2008 and the first to prohibit a concentration that did not meet the reporting threshold [1]. - The SAMR has mandated that the parties involved take measures to restore the situation to its pre-concentration state [1]. Group 2: Market Impact - The concentration involves the drug "Papaverine Hydrochloride Injection," which is crucial for treating various vascular spasms and has no effective substitutes [1]. - Wuhan Yuntong has a dominant market share in the upstream raw material supply, controlling 90%-95% of the market from 2019 to 2022, indicating strong market power [2]. - The concentration is believed to have led to a significant increase in the price of Papaverine Hydrochloride Injection, with an average factory price rising over 400% from 2017 to 2018, and a further increase of 60%-65% in 2019 [2][3]. Group 3: Future Implications - The SAMR's decision aims to eliminate Wuhan Yuntong's control over the Papaverine Hydrochloride Injection market, promoting fair competition and protecting consumer rights [3]. - The case is currently under further review, with a deadline for completion set for August 18, 2025 [3].